- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05843578
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Many patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the safety, pharmacokinetics, and pharmacodynamics of AGMB-129 in patients with Crohn's disease and symptomatic strictures, and whether it can have a beneficial effect on intestinal strictures.
The participants will be in the study for a total duration of up to 19 weeks, including a 5-week screening period, a 12-week double-blind, placebo-controlled treatment period where they will receive either a high or low dose or placebo (1:1:1), and 2-week safety follow-up period
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, placebo-controlled, double-blind, parallel, multicenter, phase 2a study in participants with Crohn's disease and symptomatic intestinal strictures.
This study consists of 3 periods (a screening period, a placebo-controlled, double-blind treatment period, and safety follow-up). After signing informed consent, eligibility will be assessed during a 5-week screening period. The presence of qualifying intestinal strictures will be assessed by ileocolonoscopy and magnetic resonance enterography (MRE). The presence of obstructive symptoms will be also evaluated.
Eligible participants will be randomized 1:1:1 to receive AGMB-129 high dose, low dose or placebo for 12 weeks.
During Screening and Week 12 visits, participants will undergo ileocolonoscopy with biopsy collection for exploring pharmacodynamics. Participants will have blood sample collection at Weeks 2, 4, 8, and 12 to assess safety, pharmacokinetics, and pharmacodynamics.
Throughout the study, participants will undergo routine safety assessments at study visits, which will include physical examination, vital signs, clinical laboratory assessment, electrocardiogram (ECG), and recording of AEs.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tim Van Kaem
- Phone Number: +3233023530
- Email: clinicalstudies@agomab.com
Study Locations
-
-
-
Graz, Austria, 8036
- Recruiting
- Medical University of Graz
-
Salzburg, Austria, 5020
- Recruiting
- Gemeinnutzige Salzburger Landeskliniken Betriebsgesellschaft mbH (Landeskrankenhaus Salzburg/Regional Hospital Salzburg)
-
Vienna, Austria, 1090
- Recruiting
- Medical University Of Vienna (AKH Wien)
-
-
-
-
-
Calgary, Canada, AB T2N 4Z6
- Recruiting
- University of Calgary
-
Edmonton, Canada, T5R1W2
- Not yet recruiting
- Gastroenterology and Internal Medicine Research Institute (GIRI)
-
Edmonton, Canada, T6K 4B2
- Recruiting
- South Edmonton Gastroenterology Research Clinic
-
North York, Canada, ON M6A 3B4
- Recruiting
- TIDHI Innovation Inc.
-
Vancouver, Canada, BC V6Z 2K5
- Recruiting
- (G.I.R.I) GI Research Institute
-
-
-
-
-
Copenhagen, Denmark, 2400
- Recruiting
- Bispebjerg Hospital
-
Herlev, Denmark, 2730
- Recruiting
- Herlev Hospital (University of Copenhagen)
-
Odense, Denmark, 5000
- Recruiting
- Odense University Hospital
-
-
-
-
-
Berlin, Germany, 14163
- Recruiting
- Servicegesellschaft Krankenhaus Waldfriede mbH Krankenhaus Waldfriede e.V Akademisches Lehrkrankenhaus der Charite
-
Berlin, Germany, 12203/12200
- Recruiting
- Charite Universitatsmedizin Berlin KöR Campus Benjamin Franklin Medizinische
-
Halle, Germany, 06108
- Recruiting
- BSF Studiengesellschaft UG (Unternehmergesellschaft, haftungsbeschränkt)
-
Ulm, Germany, 89081
- Recruiting
- Universitatsklinikum Ulm AöR (University of Ulm)
-
-
-
-
-
Milan, Italy, 20089
- Recruiting
- Humanitas Research Hospital IRCCS Istituto Clinico Humanitas
-
Modena, Italy, 41124
- Recruiting
- Azienda Ospedaliero Universitaria di Modena - Struttura Complessa di Gastroenterologia
-
Rome, Italy, 00152
- Recruiting
- Azienda Ospedaliera San Camillo Forlanini
-
-
-
-
-
Katowice, Poland, 40-748
- Recruiting
- Vita Longa Sp. z.o.o.
-
Lublin, Poland, 20-582
- Recruiting
- MEDRISE Sp. z o.o.
-
Warsaw, Poland, 00-728
- Recruiting
- WIP Warsaw IBD Point
-
Wrocław, Poland, 52210
- Recruiting
- PlanetMed Sp. z o.o.
-
-
-
-
-
Barcelona, Spain, 08036
- Recruiting
- Hospital Clínic de Barcelona
-
Las Palmas De Gran Canaria, Spain, 35010
- Recruiting
- Hospital Universitario de Gran Canaria
-
Sevilla, Spain, 41013
- Recruiting
- Hospital Universitario Virgen del Rocio
-
-
-
-
Connecticut
-
Hamden, Connecticut, United States, 06518
- Not yet recruiting
- Medical Research Center of Connecticut, LLC
-
Contact:
- PACT Gastroenterology Center
- Phone Number: 203-281-5161
- Email: mrcc@gastrocenter.org
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Contact:
- Phone Number: 305-243-8644
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- Gastroenterology Clinic | Taubman Center
- Phone Number: 888-229-7408
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Phone Number: 507-512-7446
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- IBD Clinical Trials Coordinator
- Phone Number: 7 314-747-4236
- Email: ibdstudy@wustl.edu
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Phone Number: 216-444-7000
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of ileal or ileocolonic CD based on supporting guideline criteria (eg, clinical, endoscopic, and histologic evidence) established at least 3 months prior to screening.
Presence of at least 1 stricture in the terminal ileum within reach of an endoscope (passable or nonpassable).Strictures should be noncritical, naïve or anastomotic stricture(s), caused by CD and confirmed centrally by MRE according to the following criteria:
- Localized luminal narrowing (luminal diameter ≤50% relative to normal adjacent bowel); AND
- Bowel wall thickening (≥25% relative to adjacent bowel; AND
- Either prestenotic dilation (defined as a luminal diameter ≥3 cm) or nonpassable with adult colonoscope
- Presence of tolerable obstructive symptoms, as defined by a screening S-PRO severity score ≥2, and not expected to require hospitalization, endoscopic balloon dilation, surgical resection, or additional therapy during the study. Participant should have sufficient food intake, even with diet modification.
- Stable background therapy for CD and agree to maintain background therapy for the study duration
Exclusion criteria:
- History or current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug-induced colitis, idiopathic colitis (ie, colitis not consistent with CD), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption.
- CD-related complications (previous extensive small bowel resection, ileorectal anastomosis, proctocolectomy, short bowel syndrome, ileostomy [diverting or end], colostomy, small bowel stoma, ileoanal pouch, inactive fistulae in or adjacent to an ileal stricture, anal and perianal stricture, active intra-abdominal or perianal abscess that has not been appropriately treated, abscess in relation to the stricture, toxic megacolon, very severe inflammation, or presence of deep ulceration in the colon or terminal ileum).
- Ileitis not associated with CD (eg, ileitis associated with infections, spondyloarthropathies, ischemia, etc.).
- Endoscopic balloon dilation or surgical treatment of the same small bowel stricture within the last 6 months prior to screening
- Receiving cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of screening or Janus kinase inhibitor therapy within 4 weeks of screening.
- Requiring continued treatment with systemically administered medications that are sensitive CYP3A4/5 substrates with a narrow therapeutic index or strong inhibitors of aldehyde oxidase or xanthine oxidase.
- Current or history of vasculitis, valvulopathy or large vessel disorder or major abnormalities documented by cardiac echocardiography with Doppler
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Placebo
Matching placebo
|
Matching oral capsule
|
Experimental: AGMB-129 High
AGMB-129 high dose
|
Oral capsule
|
Experimental: AGMB-129 Low
AGMB-129 low dose
|
Oral capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: From Screening to Week 12
|
To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of adverse events at every visit
|
From Screening to Week 12
|
Number of participants with abnormal clinical laboratory values
Time Frame: From Screening to Week 12
|
To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of abnormal laboratory parameters at every visit
|
From Screening to Week 12
|
Number of participants with abnormal ECG parameters
Time Frame: From Screening to Week 12
|
To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of abnormal ECG parameters at every visit
|
From Screening to Week 12
|
Number of participants with abnormal vital signs
Time Frame: From Screening to Week 12
|
To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of vital signs at every visit
|
From Screening to Week 12
|
Number of participants with abnormal physical exams
Time Frame: From Screening to Week 12
|
To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of physical exams at every visit
|
From Screening to Week 12
|
Number of participants with abnormal 2D-echocardiography
Time Frame: From Screening to Week 12
|
To evaluate the safety and tolerability of AGMB-129 between AGMB-129 participants and placebo participants in terms of echocardiography at week 12
|
From Screening to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma levels of AGMB-129 and its metabolites
Time Frame: From Baseline to Week 12
|
To characterize the pharmacokinetics (PK) of AGMB-129 and its metabolites by measuring the amount in plasma
|
From Baseline to Week 12
|
Changes in mRNA gene expression in ileal biopsies
Time Frame: From Baseline to Week 12
|
To characterize the pharmacodynamics of AGMB-129 by determining the gene expression in ileal biopsies
|
From Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Philippe Wiesel, MD, Agomab Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGMB-129-C102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrostenotic Crohn's Disease
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on AGMB-129
-
Agomab Spain S.L.CompletedHealthy VolunteersBelgium
-
Agomab Spain S.L.Recruiting
-
Origo BiopharmaCompleted
-
Children's Hospital Medical Center, CincinnatiNational Institutes of Health (NIH)RecruitingObstructive Sleep ApneaUnited States
-
Betta Pharmaceuticals Co., Ltd.RecruitingHead and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Solid TumorChina
-
Five Eleven Pharma, Inc.CompletedAlzheimer DiseaseUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingRespiratory DisordersUnited States
-
Dr. Grace ParragaAstraZenecaActive, not recruiting
-
Children's Hospital Medical Center, CincinnatiRecruitingRespiratory DisordersUnited States
-
Swiss Federal Institute of TechnologyUniversity Hospital, Zürich; Swiss Federal Food Safety and Veterinary OfficeCompleted